Physician profile
Sarah Lim
NPI 1891051959
$4,970.12
in general payments reported to CMS, 2019-2025
36 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $1,224 · 2023: $1,361 · 2024: $1,589 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $839.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $755.97 | 2022-2025 | |
| Lilly USA, LLC | $633.49 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $407.38 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $367.39 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $301.66 | 2022-2025 | Otezla, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.39 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.80 | 2023-2024 | Synjardy, Tradjenta, Jardiance |
| Dexcom, INC. | $117.84 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $112.21 | 2022 | |
| Glaxosmithkline, LLC. | $104.97 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $89.74 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $80.83 | 2022 | |
| Neurocrine Biosciences, INC. | $79.30 | 2025 | |
| Sanofi-Aventis U.S. LLC | $74.46 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $67.41 | 2023-2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $62.56 | 2023 | |
| Exact Sciences Corporation | $61.65 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $57.57 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $49.23 | 2025 | Gemtesa |
| Daiichi Sankyo INC. | $40.88 | 2024-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $29.83 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $27.25 | 2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $26.82 | 2024 | Rexulti |
| Atricure, INC. | $25.34 | 2023 | |
| Corium, LLC | $20.51 | 2023 | Azstarys |
| Stryker Corporation | $19.24 | 2025 | Clottriever Bold Catheter |
| Abbott Laboratories | $19.22 | 2022 | |
| Halozyme INC | $18.59 | 2023 | |
| Bausch Health US, LLC | $18.12 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.92 | 2023 | Xyosted, Qelbree |
| Aimmune Therapeutics, INC. | $17.27 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $16.82 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.00 | 2023 | |
| Shield Therapeutics INC | $13.70 | 2024 | |
| Amneal Pharmaceuticals LLC | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.